89 related articles for article (PubMed ID: 21298150)
1. On the cutting edge: protease-sensitive prodrugs for the delivery of photoactive compounds.
Gabriel D; Zuluaga MF; Lange N
Photochem Photobiol Sci; 2011 May; 10(5):689-703. PubMed ID: 21298150
[TBL] [Abstract][Full Text] [Related]
2. It is all about proteases: from drug delivery to in vivo imaging and photomedicine.
Gabriel D; Zuluaga MF; van den Bergh H; Gurny R; Lange N
Curr Med Chem; 2011; 18(12):1785-805. PubMed ID: 21466472
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
Gabriel D; Busso N; So A; van den Bergh H; Gurny R; Lange N
J Control Release; 2009 Sep; 138(3):225-34. PubMed ID: 19445983
[TBL] [Abstract][Full Text] [Related]
4. Enhanced prostate cancer targeting by modified protease sensitive photosensitizer prodrugs.
Zuluaga MF; Gabriel D; Lange N
Mol Pharm; 2012 Jun; 9(6):1570-9. PubMed ID: 22548315
[TBL] [Abstract][Full Text] [Related]
5. Polymeric photosensitizer prodrugs for photodynamic therapy.
Campo MA; Gabriel D; Kucera P; Gurny R; Lange N
Photochem Photobiol; 2007; 83(4):958-65. PubMed ID: 17645670
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated prodrugs: strategies, challenges, and future directions.
Poreba M
FEBS J; 2020 May; 287(10):1936-1969. PubMed ID: 31991521
[TBL] [Abstract][Full Text] [Related]
7. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Subr V
Adv Drug Deliv Rev; 2004 Apr; 56(7):1023-50. PubMed ID: 15066758
[TBL] [Abstract][Full Text] [Related]
8. Synthetic artificial peptidases and nucleases using macromolecular catalytic systems.
Suh J
Acc Chem Res; 2003 Jul; 36(7):562-70. PubMed ID: 12859217
[TBL] [Abstract][Full Text] [Related]
9. Controlled systemic release of therapeutic peptides from PEGylated prodrugs by serum proteases.
Nollmann FI; Goldbach T; Berthold N; Hoffmann R
Angew Chem Int Ed Engl; 2013 Jul; 52(29):7597-9. PubMed ID: 23766125
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical approaches to colon targeted drug delivery systems.
Chourasia MK; Jain SK
J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeting macromolecular therapeutics.
Wang D; Miller SC; Kopecková P; Kopecek J
Adv Drug Deliv Rev; 2005 May; 57(7):1049-76. PubMed ID: 15876403
[TBL] [Abstract][Full Text] [Related]
12. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
13. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
14. Protease-mediated arsenic prodrug strategy in cancer and infectious diseases: a hypothesis for targeted activation.
Bellacchio E; Paggi MG
J Cell Physiol; 2008 Mar; 214(3):681-6. PubMed ID: 17894417
[TBL] [Abstract][Full Text] [Related]
15. Potential photoactivated metallopharmaceuticals: from active molecules to supported drugs.
Crespy D; Landfester K; Schubert US; Schiller A
Chem Commun (Camb); 2010 Sep; 46(36):6651-62. PubMed ID: 20717579
[TBL] [Abstract][Full Text] [Related]
16. Disentanglement of protease substrate repertoires.
Van Damme P; Vandekerckhove J; Gevaert K
Biol Chem; 2008 Apr; 389(4):371-81. PubMed ID: 18208357
[TBL] [Abstract][Full Text] [Related]
17. Chitosan-based nanogels for selective delivery of photosensitizers to macrophages and improved retention in and therapy of articular joints.
Schmitt F; Lagopoulos L; Käuper P; Rossi N; Busso N; Barge J; Wagnières G; Laue C; Wandrey C; Juillerat-Jeanneret L
J Control Release; 2010 Jun; 144(2):242-50. PubMed ID: 20152870
[TBL] [Abstract][Full Text] [Related]
18. Protease proteomics: revealing protease in vivo functions using systems biology approaches.
Doucet A; Overall CM
Mol Aspects Med; 2008 Oct; 29(5):339-58. PubMed ID: 18571712
[TBL] [Abstract][Full Text] [Related]
19. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.
Singh R; Browning JL; Abi-Habib R; Wong K; Williams SA; Merchant R; Denmeade SR; Buckley TJ; Frankel AE
Anticancer Drugs; 2007 Aug; 18(7):809-16. PubMed ID: 17581303
[TBL] [Abstract][Full Text] [Related]
20. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
